Study in mice significantly slowed liver tumour growth and activated anti-tumour immune response, highlighting an effective immunotherapy for liver cancer.
List view / Grid view
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
A study has shown that blocking the gene expression of MAGEA3 in liver cancer cells prevents the tumour from proliferating.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
A new discovery that healthy liver tissue surrounding a tumour activates a defence mechanism that restrains tumour growth could inspire new therapeutic approaches that mobilise normal cells to kill cancer cells.
The involvement of clathrin in the development of liver cancer has been described for the first time, which could lead to more targeted therapy.
A cellular pathway may reduce side effects and extend immunotherapy duration in patients with the most common form of liver cancer.
Stem cells transformed into 3D human liver tissue by scientists show promising support of liver function when implanted into mice with a liver disease...
Researchers have discovered that FFW and Sorafenib used together could reduce the growth of Sorafenib resistant hepatocellular carcinoma tumours...